Pharmaceutical

Dyadic to Present at BioProcess International

JUPITER, Fla., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology…

9 months ago

Xenon Pharmaceuticals Announces Upcoming Investor Webinar with Leading Key Opinion Leaders to Discuss XEN1101 and Major Depressive Disorder

Live broadcast of webinar on Tuesday, September 19 beginning at 11:30 am ETVANCOUVER, British Columbia, Sept. 12, 2023 (GLOBE NEWSWIRE)…

9 months ago

Poolbeg Pharma PLC Announces Interim Results for the Six Months to 30 June 2023

Significant progress made and well positioned for future growthLONDON, UK / ACCESSWIRE / September 13, 2023 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF),…

9 months ago

Amphastar Pharmaceuticals Announces Pricing of Offering of $300.0 Million of Convertible Senior Notes

RANCHO CUCAMONGA, CA / ACCESSWIRE / September 13, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar") today announced the pricing of…

9 months ago

Lucy Scientific Discovery Expands its Reach in the Global Wellness Market with BlueSky Wellness Acquisition

VANCOUVER, BC / ACCESSWIRE / September 12, 2023 / Lucy Scientific Discovery Inc. (NASDAQ:LSDI), a publicly traded company focused on…

9 months ago

Orthofix Announces Leadership Changes

Catherine Burzik Appointed Interim Chief Executive Officer Geoffrey Gillespie Appointed Interim Chief Financial Officer Puja Leekha Appointed Interim Chief Legal…

9 months ago

GoodCap Pharmaceuticals Announces Publication of Positive Results from Two Studies Relating to GoodCap’s Lead Drug Candidate

Toronto, Ontario--(Newsfile Corp. - September 12, 2023) - GoodCap Pharmaceuticals Inc. ("GoodCap" or the "Company"), a leading biopharmaceutical company focused…

9 months ago

Cosmos Health Introduces Guidance; Expects to Achieve Over $180M in Gross Annual Revenue and EBITDA in Excess of $20M by 2026; Recaps Significant Events Reported So Far in 2023

Company reaches major strategic inflection point, with operations and revenue ramp-up underwayInaugural 2026 guidance introduced; target to achieve:More than $180…

9 months ago

New Bausch Health Treatment PrUCERIS(R) (budesonide) Aerosol Foam Now Available Across Canada to Treat Mild to Moderate Distal Ulcerative Colitis in Adults

LAVAL, QE / ACCESSWIRE / September 12, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is pleased to announce that following…

9 months ago